Skip Nav Destination

Issue Archive

Select Year

Issue

Volume 1, Issue 2

June 21 2024

In this Issue

REVIEW ARTICLE
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
RESEARCH LETTERS

REVIEW ARTICLE

A novel application of XPO1 inhibition for the treatment of myelofibrosis

Megan Metzger,Zachary M. Avigan,Pankit Vachhani,Julian Waksal,John Mascarenhas

View Articletitled, A novel application of XPO1 inhibition for the treatment of myelofibrosis

LYMPHOID NEOPLASIA

Central role of the mTORC1 pathway in glucocorticoid activity against B-ALL cells

Hiroshi Imanaga,Yuichiro Semba,Kensuke Sasaki,Kiyoko Setoguchi,Hillary Maniriho,Takuji Yamauchi,Tatsuya Terasaki,Shigeki Hirabayashi,Fumihiko Nakao,Jumpei Nogami,Shai Izraeli,Koichi Akashi,Takahiro Maeda

View Articletitled, Central role of the mTORC1 pathway in glucocorticoid activity against B-ALL cells

Supplemental data

The landscape of rare genetic variants in familial Waldenström macroglobulinemia

Alexander Pemov,Jung Kim,Wen Luo,Jia Liu,Cole Graham,Kristine Jones,Delphine DeMangel,Neal D. Freedman,Charles Dumontet,Bin Zhu,Mary L. McMaster,Douglas R. Stewart

View Articletitled, The landscape of rare genetic variants in familial Waldenström macroglobulinemia

Supplemental data

MYELOID NEOPLASIA

Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial
Clinical Trials & Observations

Timothy S. Pardee,Bayard L. Powell,Richard A. Larson,Joseph Maly,Michael Keng,Matthew Foster,Eun-Ji Choi,Heinz Sill,Thomas Cluzeau,Deepa Jeyakumar,Olga Frankfurt,Prapti Patel,Michael Schuster,Elisabeth Koller,Regis Costello,Uwe Platzbecker,Pau Montesinos,Susana Vives,Aziz Nazha,Rachel Cook,Carlos Vigil-Gonzales,Sylvain Chantepie,Sanjeev Luther,Jorge Cortes

View Articletitled, Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial

Supplemental data

Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML

Samuel Urrutia,Prithviraj Bose,Yesid Alvarado,Gautam Borthakur,Farhad Ravandi,Naval Daver,Naveen Pemmaraju,Elias Jabbour,Koichi Takahashi,Tapan Kadia,Courtney DiNardo,Steven Kornblau,Rashmi Kanagal-Shamanna,Xuelin Huang,Kristy Bodden,Hagop Kantarjian,Guillermo Garcia-Manero

View Articletitled, Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML

Supplemental data

CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib

Chung Hoow Kok,Yazad Irani,Jade Clarson,Verity Saunders,Phuong Dang,Naranie Shanmuganathan,Susan Branford,David Yeung,Agnes S. M. Yong,Timothy P. Hughes

View Articletitled, CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib

Supplemental data

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia

Ellen Madarang,Jillian Lykon,Wei Zhao,Mikkael A. Sekeres,Terrence Bradley,Namrata S. Chandhok,Justin Taylor,Sangeetha Venugopal,Tulay Koru-Sengul,Sunil Girish Iyer,Jason S. Gilbert,Ryan M. Miller,Jacopo Nanni,Irene Zacheo,Agnese Mattei,Najla Al Ali,Ashwin Kishtagari,Giovanni Marconi,David A. Sallman,Daniel A. Pollyea,Michael R. Savona,Cristina Papayannidis,Rami Komrokji,Justin Watts

View Articletitled, Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia

Supplemental data

RESEARCH LETTERS

Frequent response monitoring in chronic lymphocytic leukemia clinical trials: what is the value?

Agnes Mattsson,Jeanette Lundin,Tom A. Mulder,Sandra E. Sylvan,Marzia Palma,Lotta Hansson,Anders Österborg

View Articletitled, Frequent response monitoring in chronic lymphocytic leukemia clinical trials: what is the value?

Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma

Wen-Kai Weng,Chaitanya Iragavarapu,Gavin M. Weng,Richard T. Hoppe,Susan Hiniker,Michael S. Khodadoust,Youn H. Kim

View Articletitled, Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma

Supplemental data

Competition of dual SF3B1^mt clones in MDS-RS is associated with distinct RNA mis-splicing in hematopoietic stem cells

Pedro Luis Moura,Yasuhito Nannya,Affaf Aliouat,Isabel Juliana Hofman,Teresa Mortera-Blanco,Tetsuichi Yoshizato,Ryunosuke Saiki,Masahiro M. Nakagawa,Maria Creignou,Ann-Charlotte Björklund,Gunilla Walldin,Indira Barbosa,Monika Jansson,Francesca Grasso,Edda M. Elvarsdottir,Petter S. Woll,Sten Eirik W. Jacobsen,Seishi Ogawa,Eva Hellström-Lindberg

View Articletitled, Competition of dual <em>SF3B1</em><sup>mt</sup> clones in MDS-RS is associated with distinct RNA mis-splicing in hematopoietic stem cells

Supplemental data

Saliva as a feasible alternative to blood for interrogation of somatic hematopoietic variants

Eli M. Soyfer,Jianhong C. Heidmann,Gajalakshmi Ramanathan,Hellen Nguyen,Simran Bhardwaj,Jane H. Chen,Yeowon Jung,Eshika Arora,Helen Huang,Lauren Chen,Aanya Amin,Eduard Mas Marin,W. Lucas Wadley,Hew Yeng Lai,Nahid Haghighi,Angela G. Fleischman

View Articletitled, Saliva as a feasible alternative to blood for interrogation of somatic hematopoietic variants

Supplemental data

Cover Image

Cover Image

Myelodysplastic syndrome with ring sideroblasts. Iron may be distributed in the mitochondria in a typical “necklace” pattern around the nucleus or as large clusters within the cytoplasm. Image by Peter Maslak.

All Issues

Advertisement intended for health care professionals

Table of Contents

REVIEW ARTICLE

A novel application of XPO1 inhibition for the treatment of myelofibrosis

LYMPHOID NEOPLASIA

Central role of the mTORC1 pathway in glucocorticoid activity against B-ALL cells

The landscape of rare genetic variants in familial Waldenström macroglobulinemia

MYELOID NEOPLASIA

Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial
Clinical Trials & Observations

Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML

CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia

RESEARCH LETTERS

Frequent response monitoring in chronic lymphocytic leukemia clinical trials: what is the value?

Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma

Competition of dual SF3B1^mt clones in MDS-RS is associated with distinct RNA mis-splicing in hematopoietic stem cells

Saliva as a feasible alternative to blood for interrogation of somatic hematopoietic variants

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

REVIEW ARTICLE

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial Clinical Trials & Observations

RESEARCH LETTERS

Cover Image

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial
Clinical Trials & Observations